Dechra Pharmaceuticals PLC
ISIN: GB0009633180 | Ticker: DPH | LEI: 213800J4UVB5OWG8VX82
Country: United Kingdom
Dechra Pharmaceuticals PLC is a global veterinary pharmaceutical company that specializes in developing and marketing high-quality products for the treatment of animals. Founded in 1997, the company has grown to become a major player in the animal health industry, with a presence in over 45 countries around the world.
Dechra Pharmaceuticals PLC is committed to improving the lives of animals through its innovative and effective products. The company's portfolio includes a wide range of products, including pharmaceuticals, vaccines, and nutritional supplements, for a variety of species, including dogs, cats, horses, and farm animals.
1997
Served areaWorldwide
Headcount2,036
Headquarters24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, CW9 7UA Northwich – United Kingdom
| Line item in (gbp) | 01.07.2020 | 01.07.2021 | 01.07.2022 |
|---|---|---|---|
| Assets | N/A | 1,214,100,000.00 | 1,293,300,000.00 |
| Noncurrent Assets | N/A | 821,900,000.00 | 848,900,000.00 |
| Property Plant And Equipment | N/A | 87,000,000.00 | 100,300,000.00 |
| Investments In Associates Accounted For Using Equity Method | N/A | 17,100,000.00 | 15,800,000.00 |
| Deferred Tax Assets | N/A | 2,000,000.00 | 2,300,000.00 |
| Current Assets | N/A | 392,200,000.00 | 444,400,000.00 |
| Inventories | N/A | 149,500,000.00 | 175,700,000.00 |
| Trade And Other Current Receivables | N/A | 106,700,000.00 | 136,800,000.00 |
| Current Tax Assets Current | N/A | 17,600,000.00 | 11,000,000.00 |
| Cash and cash equivalents | 227,400,000.00 | 118,400,000.00 | 120,900,000.00 |
| Equity | 637,500,000.00 | 632,900,000.00 | 666,800,000.00 |
| Issued Capital | N/A | 1,100,000.00 | 1,100,000.00 |
| Retained Earnings | N/A | 147,700,000.00 | 164,000,000.00 |
| Share Premium | N/A | 411,600,000.00 | 413,900,000.00 |
| Merger Reserve | N/A | 84,400,000.00 | 84,400,000.00 |
| Liabilities | N/A | 581,200,000.00 | 626,500,000.00 |
| Noncurrent Liabilities | N/A | 425,400,000.00 | 467,800,000.00 |
| Noncurrent Provisions | N/A | 3,500,000.00 | 2,200,000.00 |
| Deferred Tax Liabilities | N/A | 48,800,000.00 | 35,800,000.00 |
| Current Liabilities | N/A | 155,800,000.00 | 158,700,000.00 |
| Trade And Other Current Payables | N/A | 113,500,000.00 | 136,800,000.00 |
| Current Tax Liabilities Current | N/A | 16,600,000.00 | 12,200,000.00 |
| Line item in (gbp) | 01.07.2020/ 01.07.2021 |
01.07.2021/ 01.07.2022 |
|---|---|---|
| Revenue | 608,000,000.00 | 681,800,000.00 |
| Profit Loss From Operating Activities | 84,000,000.00 | 95,500,000.00 |
| Finance Income | 3,800,000.00 | 5,700,000.00 |
| Finance Costs | 12,700,000.00 | 22,300,000.00 |
| Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method | -1,100,000.00 | -1,300,000.00 |
| Profit Loss Before Tax | 74,000,000.00 | 77,600,000.00 |
| Income Tax Expense Continuing Operations | 18,500,000.00 | 19,400,000.00 |
| Profit (loss) | 55,500,000.00 | 58,200,000.00 |
| Line item in (gbp) | 01.07.2020 | 01.07.2021 | 01.07.2022 |
|---|---|---|---|
| Profit (loss) | N/A | 55,500,000.00 | 58,200,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -36,600,000.00 | -19,300,000.00 |
| Adjustments For Sharebased Payments | N/A | 2,800,000.00 | 3,300,000.00 |
| Cash Flows From Used In Operations | N/A | 141,200,000.00 | 163,300,000.00 |
| Cash Flows From Used In Operating Activities | N/A | 89,100,000.00 | 122,900,000.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 900,000.00 | 800,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 200,000.00 | 0.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 18,900,000.00 | 20,300,000.00 |
| Proceeds From Sales Of Intangible Assets Classified As Investing Activities | N/A | 200,000.00 | 0.00 |
| Interest Received Classified As Investing Activities | N/A | 0.00 | 100,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -136,100,000.00 | -78,300,000.00 |
| Proceeds From Issuing Shares | N/A | 2,300,000.00 | 2,300,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 15,900,000.00 | 0.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 3,600,000.00 | 3,600,000.00 |
| Dividends Paid Classified As Financing Activities | N/A | 37,900,000.00 | 44,800,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -55,100,000.00 | -46,100,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -102,100,000.00 | -1,500,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -6,900,000.00 | 4,000,000.00 |
| Cash and cash equivalents | 227,400,000.00 | 118,400,000.00 | 120,900,000.00 |
Please note that some sums might not add up.
| Position Holder | Short Interest in Percent | Date |
|---|---|---|
| Qube Research & Technologies Limited | 1.51% | 18.10.23 |
| Qube Research & Technologies Limited | 0.95% | 20.12.23 |
| Qube Research & Technologies Limited | 1.37% | 09.11.23 |
| Qube Research & Technologies Limited | 1.07% | 10.08.23 |
| Qube Research & Technologies Limited | 0.89% | 27.12.23 |
| Qube Research & Technologies Limited | 1.29% | 01.12.23 |
| Qube Research & Technologies Limited | 1.40% | 12.10.23 |
| Qube Research & Technologies Limited | 1.18% | 11.12.23 |
| Qube Research & Technologies Limited | 1.32% | 21.09.23 |
| Qube Research & Technologies Limited | 1.29% | 22.11.23 |
| Qube Research & Technologies Limited | 1.36% | 24.08.23 |
| Qube Research & Technologies Limited | 0.79% | 10.01.24 |
| Qube Research & Technologies Limited | 1.31% | 30.11.23 |
| Qube Research & Technologies Limited | 1.28% | 07.09.23 |
| Qube Research & Technologies Limited | 1.40% | 27.09.23 |
| Total | 18.41% |
GB0009633180
LEI213800J4UVB5OWG8VX82
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryFTSE 250
Main Stock ExchangeKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.